Posted by Michael Wonder on 04 Apr 2017
AbbVie announces Ibrutinib (Imbruvica) supplemental new drug application for previously treated chronic graft-versus-host-disease accepted for review by U.S. FDA
4 April 2017 - AbbVie today announced a supplemental new drug application was accepted for review by the U.S. FDA for ibrutinib (imbruvica) in chronic graft-versus-host-disease after failure of one or more lines of systemic therapy.
Chronic graft-versus-host disease is a severe, potentially life-threatening consequence of stem cell or bone marrow transplant. If approved by the U.S. FDA, ibrutinib will be the first therapy specifically approved to treat this condition.
Imbruvica is jointly developed and commercialised by Pharmacyclics, an AbbVie company, and Janssen Biotech, Inc.
